TCR-T cell therapies

JSON for agents All formats →

A T-cell receptor engineered to see a peptide from inside the cell presented on an HLA molecule: the antigen and the HLA restriction together decide who the medicine can treat. The grid below is target against hla restriction: 4 by 1 from 5 medicines, 1 combinations approved, 4 in development, 0 tried and stopped, 2 untried in this corpus.

Antibody-drug conjugates Radioligands CAR cell therapies TCR-T cell therapies Bispecific antibodies Degraders and molecular glues Small-molecule inhibitors Naked antibodies Cytokines Cancer vaccines Oncolytic viruses Other cell therapies

Approved 1In development 4Tried and stopped 0Recorded, state unclear 0Untried here 24 target rows x 1 hla restriction columns. Click a cell to filter the table.

Target \ HLA restriction

Every tried combination

5 combinations

			Medicines					Records	Stopped, and why
CTAG1B	HLA restriction not recorded	In development	TBI-1301	0	1	-	-	trial: Multi-center Study of TBI-1301 (INN: Mipetresge…registry: ClinicalTrials.gov: 1 recruiting, active or pla…record: Drug record status: phase 3	-
CTAG1B	HLA-A*02	In development	Letetresgene autoleucel	0	1	Autologous	Affinity-enhanced TCR	registry: ClinicalTrials.gov: 1 recruiting, active or pla…record: Drug record status: phase 2	-
Claudin 18.2	HLA restriction not recorded	In development	TAC01-CLDN18.2	0	1	Autologous	T-cell antigen coupler	trial: TAC T-cells for the Treatment of Claudin 18.2 P…registry: ClinicalTrials.gov: 1 recruiting, active or pla…record: Drug record status: phase 2	-
MAGE-A4	HLA-A*02	Approved	Afamitresgene autoleucel	1	0	-	Affinity-enhanced TCR	approval: US 2024: Advanced MAGE-A4+ synovial sarcoma, HL…regulator: FDA (US): approved 2024 trial: Spearhead 1 Study in Subjects With Advanced Syn…trial: SPEARHEAD-3 Pediatric Study: phase 1/2, recruit…+2 more	-
PRAME	HLA restriction not recorded	In development	IMA203	0	1	Autologous	-	trial: SUPRAME-ACTengine® IMA203 vs. Investigator's Ch…registry: ClinicalTrials.gov: 2 recruiting, active or pla…record: Drug record status: phase 3	-

Stopped, and why

0 medicines recorded as stopped; 0 recorded reasons, including stopped studies of medicines still in development

No stopped study, withdrawn approval or negative result is recorded for a medicine in this format.

Not placed

0 of 5 medicines in this format (0%)

Every medicine in this format has its target on a record.

How this grid is read from the records

Each medicine's parts come from its own record: the targets field first, else the target records that list the medicine, else a sibling conjugate that shares its antibody name, else the trials linked to it, else the target names the corpus knows found in its modality, mechanism or summary text. The second part is read from the medicine's technology links first and from its modality and mechanism text second; a part no record names is shown as not recorded. Every part carries the fields it was read from and a confidence in the JSON file.

What the states mean, and do not

Approved: a medicine in the cell has an approval row or a regulator's approved entry and is not recorded as withdrawn. In development: a recruiting, active or planned trial, a development-phase record status, or active studies in the ClinicalTrials.gov index, and no approval. Tried and stopped: every medicine in the cell is withdrawn, negative or historic, or its only trial evidence is a terminated, withdrawn or negative study, or its approval was withdrawn. Untried: no medicine in this corpus combines the two parts.

A cell is coloured by its strongest medicine; the table shows each medicine with its own state. The reasons quoted under Stopped, and why are the records' words, including the registry's whyStopped text where the sponsor wrote one, and include stopped studies of medicines that are still in development elsewhere. Nothing here is medical advice.